ReviewScientifica2013
Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.
Review in Scientifica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Guideline
- Laboratory Diagnostics of Aspergillosis: Present State and Future Directions.Journal of fungi (Basel, Switzerland) · 2026Review
- Potential Diagnostic and Research Applications of a Recombinant Antibody Directed Against Ferrated Triacetylfusarinine C fromJournal of fungi (Basel, Switzerland) · 2026Article
- When Ear Pain Signals More: Otomastoiditis-Related Bilateral Cranial Neuropathies in an Immunocompromised Patient.Cureus · 2026Article
- The evolution of next-generation lateral flow assays for bacterial and fungal diagnostics.Mikrochimica acta · 2026Review
- Editing gliA, gliP and gliZ of Aspergillus fumigatus Using CRISPR/Cas System Renders Fungus Incapable to Produce Gliotoxin.Molecular biotechnology · 2026Article
- Prevalence and Factors Associated WithOpen forum infectious diseases · 2026Article
- Mechanistic Insights into Calcium Oxalate Crystals in Aspergillosis of the Maxillary Sinus.Head and neck pathology · 2026Article
- Beyond detection: quantitative interpretation ofFrontiers in cellular and infection microbiology · 2026Article
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- Review
- Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19.Current microbiology · 2024Review
- Aneurysm, meningitis, and subarachnoid hemorrhage secondary to intracranialQuantitative imaging in medicine and surgery · 2024Article
- Uncovering the diversity of pathogenic invaders: insights into protozoa, fungi, and worm infections.Frontiers in microbiology · 2024Review
- Antifungal Susceptibility and Genotypic Analysis ofInfection and drug resistance · 2024Article
- Cross-sectional investigation of mycological diagnosis challenges in Saudi Arabia.Frontiers in cellular and infection microbiology · 2023Article
- Growth Performance and Recovery of NosocomialMicroorganisms · 2022Article
- Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets.Pathogens (Basel, Switzerland) · 2022Review
- Performance of the Bronchoalveolar Lavage Fluid Aspergillus Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Diagnostic Performance of (1→3)-β-D-Glucan Alone and in Combination withJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive aspergillosis (IA), an infection caused by fungi in the genus Aspergillus, is seen in patients with immunological deficits, particularly acute leukaemia and stem cell transplantation, and has been associated with high rates of mortality in previous years. Diagnosing IA has long been problematic owing to the inability to culture the main causal agent A. fumigatus from blood. Microscopic examination and culture of respiratory tract specimens have lacked sensitivity, and biopsy tissue for histopathological examination is rarely obtainable. Thus, for many years there has been a great interest in nonculture-based techniques such as the detection of galactomannan, β -D-glucan, and DNA by PCR-based methods. Recent meta-analyses suggest that these approaches have broadly similar performance parameters in terms of sensitivity and specificity to diagnose IA. Improvements have been made in our understanding of the limitations of antigen assays and the standardisation of PCR-based DNA detection. Thus, in more recent years, the debate has focussed on how these assays can be incorporated into diagnostic strategies to maximise improvements in outcome whilst limiting unnecessary use of antifungal therapy. Furthermore, there is a current interest in applying these tests to monitor the effectiveness of therapy after diagnosis and predict clinical outcomes. The search for improved markers for the early and sensitive diagnosis of IA continues to be a challenge.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.